ArticleCureus2025
The Novel Osteopore® Wedge in Medial Opening Wedge High Tibial Osteotomy: A Technical Note.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Polyhydroxyalkanoates in Bone Alloplastic Materials: State of the Art and Future Perspectives.Polymers · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Medial opening wedge high tibial osteotomy (MOWHTO) is a highly common procedure for correcting varus malalignment of the knee. The current gold standard for filling this osteotomy gap is autologous bone graft, which is associated with donor site morbidity. Allograft bone graft is also an alternative; however, it is associated with certain disadvantages, such as storage cost, limited supply, and the risk of infection transmission. Consequently, there has been a growing interest in and further developments of synthetic options for filling the osteotomy gap. We would like to introduce and describe the process of manufacturing and utilizing the novel Osteopore® 3D-printed, honeycomb-structured, polycaprolactone and β-tricalcium phosphate (PCL-TCP) synthetic bone wedge for filling the gap in MOWHTO. This study will also include illustrations of postoperative radiographs and CT scans to showcase bony remodeling over a period of up to 12 months. In the era of additive manufacturing and the pursuit of more biocompatible materials, the use of a patient-specific 3D-printed, honeycomb-structured, PCL-TCP bone spacer wedge in MOWHTO is promising and may serve as a viable alternative to autograft and allograft bone grafts. It offers the potential to maintain biomechanical stability and facilitate the healing of the osteotomy gap without the associated drawbacks of bone graft.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.